REGN241220C515000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Worst Performing Stocks for Tax Loss Selling – Wolfe
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
Regeneron Down 15.5% Year to Date: How to Play the Stock?
BofA Restarts Coverage of 11 Large-cap Biopharmas
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects
B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Presents New And Updated Data For Odronextamab At ASH Annual Meeting
Kodiak Stock Rallies 32% After Jefferies Upgrades to Buy
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
Stocks With Best Odds of Risk-adjusted Returns Deserve Attention: Goldman Sachs
- Regeneron Announced Novel Combination Of Pozelimab And Cemdisiran Achieved Greater Control Of Intravascular Hemolysis In Patients With Paroxysmal Nocturnal Hemoglobinuria Vs Ravulizumab
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,186
Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $1,186 From $1,184, Maintains Overweight Rating